Last reviewed · How we verify
sc-rAAV2.5IL-1Ra
At a glance
| Generic name | sc-rAAV2.5IL-1Ra |
|---|---|
| Also known as | AAVIL-1Ra, IL-1Ra |
| Sponsor | Mayo Clinic |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Safety and Pharmacodynamics of GNSC-001 Intra-articular Injection for Knee Osteoarthritis (PHASE1)
- Safety of Intra-Articular Sc-rAAV2.5IL-1Ra in Subjects With Moderate Knee OA (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- sc-rAAV2.5IL-1Ra CI brief — competitive landscape report
- sc-rAAV2.5IL-1Ra updates RSS · CI watch RSS
- Mayo Clinic portfolio CI